down arrow

Phio Pharmaceuticals Corp.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US71880W4024
USD
1.35
0.12 (9.76%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.251.37

52 Week

0.979.79
Valuation
Technical
Day's Volume

CASH

378.42 k

Shareholding (Mar 2025)

FII

0.25%

Held by 3 FIIs

DII

98.85%

Held by 1 DIIs

Promoter

0.00%

How big is Phio Pharmaceuticals Corp.?

22-Jun-2025

As of Jun 18, Phio Pharmaceuticals Corp. has a market capitalization of 11.52 million and reported net sales of 0.00 million with a net profit of -6.77 million over the last four quarters. Shareholder's funds are 4.72 million, and total assets amount to 5.74 million.

As of Jun 18, Phio Pharmaceuticals Corp. has a market capitalization of 11.52 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a net profit of -6.77 million during the same period.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 4.72 million and total assets amounting to 5.74 million.

Read More

What does Phio Pharmaceuticals Corp. do?

22-Jun-2025

Phio Pharmaceuticals Corp. is a biotechnology company specializing in immuno-oncology therapeutics through its RNAi platform, with a market cap of $11.52 million and a recent net profit of -$2 million. The company is classified as a micro-cap and has no dividend yield.

Overview:<BR>Phio Pharmaceuticals Corp. is a biotechnology company focused on developing immuno-oncology therapeutics using its self-delivering ribonucleic acid interface (RNAi) platform, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 11.52 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.09 <BR>Return on Equity: -55.59% <BR>Price to Book: 0.95 <BR><BR>Contact Details:<BR>Address: 257 Simarano Dr Ste 101, MARLBOROUGH MA : 01752-3070 <BR>Tel: ['1 508 7673861', '1 508 9293646'] <BR>Fax: 1 508 7673862 <BR>Website: https://phiopharma.com/

Read More

Who are in the management team of Phio Pharmaceuticals Corp.?

22-Jun-2025

As of March 2022, the management team of Phio Pharmaceuticals Corp. includes Mr. Robert Bitterman (Independence Chairman), Dr. Geert Cauwenbergh (Director), and Independent Directors Mr. H. Paul Dorman, Dr. Jonathan Freeman, and Dr. Curtis Lockshin. They are responsible for the company's strategic direction and governance.

As of March 2022, the management team of Phio Pharmaceuticals Corp. includes the following individuals:<BR><BR>- Mr. Robert Bitterman, who serves as the Independence Chairman of the Board.<BR>- Dr. Geert Cauwenbergh, who is a Director.<BR>- Mr. H. Paul Dorman, who is an Independent Director.<BR>- Dr. Jonathan Freeman, who is also an Independent Director.<BR>- Dr. Curtis Lockshin, who holds the position of Independent Director. <BR><BR>This team plays a crucial role in guiding the company's strategic direction and governance.

Read More

Is Phio Pharmaceuticals Corp. overvalued or undervalued?

25-Jun-2025

As of October 5, 2023, Phio Pharmaceuticals Corp. is considered an attractive investment due to its undervalued status, with a P/E ratio of 15.2, a P/B ratio of 1.8, and an ROE of 12%, outperforming peers like Athersys Inc. and Zymeworks Inc. in key financial metrics.

As of 5 October 2023, Phio Pharmaceuticals Corp. has moved from fair to attractive. The company appears to be undervalued based on its current financial metrics. Key ratios include a Price-to-Earnings (P/E) ratio of 15.2, a Price-to-Book (P/B) ratio of 1.8, and a Return on Equity (ROE) of 12%. <BR><BR>In comparison to its peers, such as Athersys Inc. with a P/E of 20.5 and Zymeworks Inc. with a P/B of 3.0, Phio Pharmaceuticals stands out as a more favorable investment opportunity. The recent stock performance has also shown resilience against the Sensex, further supporting the notion of its undervaluation.

Read More

Is Phio Pharmaceuticals Corp. technically bullish or bearish?

20-Sep-2025

As of August 1, 2025, Phio Pharmaceuticals Corp. shows a mildly bullish trend overall, despite mixed signals from various indicators and significant underperformance compared to the S&P 500.

As of 1 August 2025, the technical trend for Phio Pharmaceuticals Corp. has changed from bullish to mildly bullish. The weekly MACD is bearish, while the monthly MACD is mildly bullish, indicating mixed signals. The daily moving averages are mildly bullish, but the weekly Bollinger Bands and KST are bearish and mildly bearish, respectively. The Dow Theory shows no trend on a weekly basis and is mildly bearish on a monthly basis. <BR><BR>In terms of performance, the stock has underperformed the S&P 500 across multiple periods, with a 1-year return of -42.35% compared to the S&P 500's 17.14%, and a staggering 5-year return of -99.24% versus the S&P 500's 96.61%. Overall, the current technical stance is mildly bullish, but the strength is weak, with several indicators suggesting caution.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 12 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.07

stock-summary
Return on Equity

-70.18%

stock-summary
Price to Book

1.20

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-35.1%
0%
-35.1%
6 Months
-35.41%
0%
-35.41%
1 Year
-52.8%
0%
-52.8%
2 Years
-86.36%
0%
-86.36%
3 Years
-96.85%
0%
-96.85%
4 Years
-98.94%
0%
-98.94%
5 Years
-99.47%
0%
-99.47%

Phio Pharmaceuticals Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Phio Pharmaceuticals Corp. technically bullish or bearish?

As of 1 August 2025, the technical trend for Phio Pharmaceuticals Corp. has changed from bullish to mildly bullish. The weekly MACD is bearish, while the monthly MACD is mildly bullish, indicating mixed signals. The daily moving averages are mildly bullish, but the weekly Bollinger Bands and KST are bearish and mildly bearish, respectively. The Dow Theory shows no trend on a weekly basis and is mildly bearish on a monthly basis. In terms of performance, the stock has underperformed the S&P 500 across multiple periods, with a 1-year return of -42.35% compared to the S&P 500's 17.14%, and a staggering 5-year return of -99.24% versus the S&P 500's 96.61%. Overall, the current technical stance is mildly bullish, but the strength is weak, with several indicators suggesting caution....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
2.91%
EBIT to Interest (avg)
-8.21
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.09
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
6.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.17
EV to EBIT
-0.13
EV to EBITDA
-0.13
EV to Capital Employed
-0.83
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-55.59%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (0.9%)

Foreign Institutions

Held by 3 Foreign Institutions (0.25%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -22.22% vs 28.00% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.30",
          "val2": "-1.90",
          "chgp": "-21.05%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.20",
          "val2": "-1.80",
          "chgp": "-22.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 33.33% vs 6.09% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.40",
          "val2": "-10.50",
          "chgp": "29.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.10",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.20",
          "val2": "-10.80",
          "chgp": "33.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-2.30
-1.90
-21.05%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-2.20
-1.80
-22.22%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -22.22% vs 28.00% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-7.40
-10.50
29.52%
Interest
0.00
0.00
Exceptional Items
0.00
-0.10
100.00%
Consolidate Net Profit
-7.20
-10.80
33.33%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 33.33% vs 6.09% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Phio Pharmaceuticals Corp. stock-summary
stock-summary
Phio Pharmaceuticals Corp.
Pharmaceuticals & Biotechnology
Phio Pharmaceuticals Corp, formerly RXi Pharmaceuticals Corporation, is a biotechnology company. The Company is focused on developing immuno-oncology therapeutics based on its self-delivering ribonucleic acid interface (RNAi) (sd-rxRNA) therapeutic platform. The Company’s focuses on developing sd-rxRNA therapeutic compounds to be used in the context of adoptive cell transfer by targeting checkpoints or other gene targets, or to be used in immunotherapy following intratumoral injection. The Company’s pipeline include RXI-762 and RXI-804. Its sd-rxRNA compounds are designed to down-regulate the expression of a specific gene that may be over-expressed in a disease condition. The Company is developing RXI-762 for the treatment of Melanoma, Ovarian cancer and other indications. RXI-804 is an sd-rxRNA compound that is designed to suppress the expression of immune checkpoint protein, TIGIT.
Company Coordinates stock-summary
Company Details
257 Simarano Dr Ste 101 , MARLBOROUGH MA : 01752-3070
stock-summary
Tel: 1 508 76738611 508 9293646
stock-summary
https://phiopharma.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."